First Horizon Advisors, Inc. Biocryst Pharmaceuticals Inc Transaction History
First Horizon Advisors, Inc.
- $3.81 Billion
- Q2 2025
A detailed history of First Horizon Advisors, Inc. transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, First Horizon Advisors, Inc. holds 688 shares of BCRX stock, worth $4,953. This represents 0.0% of its overall portfolio holdings.
Number of Shares
688
Previous 688
-0.0%
Holding current value
$4,953
Previous $5,000
20.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding BCRX
# of Institutions
316Shares Held
202MCall Options Held
930KPut Options Held
553K-
Vanguard Group Inc Valley Forge, PA21.8MShares$157 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$144 Million0.0% of portfolio
-
State Street Corp Boston, MA8.51MShares$61.2 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.46MShares$60.9 Million9.06% of portfolio
-
Alkeon Capital Management LLC New York, NY5.71MShares$41.1 Million0.09% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.34B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...